Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

"Big pharma is out of excuses," writes Lawson. "The solutions Rep. Jayapal’s bill lays out for lowering the costs of prescription drugs are thoroughly practical. They will do a much better job at ensuring patients can access their medicines than the current system, which is rigged to benefit pharma CEOs and shareholders." (Image: Office of Rep. Pramila Jayapal)

"Big pharma is out of excuses," writes Lawson. "The solutions Rep. Jayapal’s bill lays out for lowering the costs of prescription drugs are thoroughly practical. They will do a much better job at ensuring patients can access their medicines than the current system, which is rigged to benefit pharma CEOs and shareholders." (Image: Office of Rep. Pramila Jayapal)

Medicare for All Will Drastically Lower Prescription Drug Prices by Taking on Pharma’s Greed

For a Medicare for All system to meaningfully lower prescription drug prices, it must give the government the power to put the patent at risk, not the patient

Alex Lawson

Rep. Pramila Jayapal’s (D-WA) recently introduced Medicare for All Act of 2019 is a powerful and comprehensive plan to make health care a right for every American. Drastically lowering the prices of prescription drugs, while ensuring that patients are always able to get the medications they need, is an essential part of that plan.

The Medicare for All Act includes a key provision, modeled after the Medicare Negotiation and Competitive Licensing Act, which would lower drug prices for all Americans by allowing the government to negotiate lower drug prices with corporations.

"Lowering the cost of prescription drugs is essential to creating a strong Medicare for All system."

And if a corporation refused to lower the price and threatened patients’ access to the medication, generic competition would be allowed using a competitive license.

Yale law professor Amy Kapczynski and Harvard professor Aaron Kesslheim demonstrated that this authority exists and is used across the government. It is simply a matter of applying the same authority to generic pharmaceutical competition. The Department of Defense has used the same authority to purchase “generic” versions of night vision lenses and lead-free bullets, and the Department of the Treasury has used the authority to purchase “generic” software.

In the United Kingdom, even though their National Health Service is a single payer, drug companies still massively overcharge for prescription drugs. For instance, the cystic fibrosis medicine Orkambi has been priced in the United Kingdom at £$104,000 per patient, per year. (In U.S. dollars, that’s currently somewhere around $130,000 to $140,000 per year.) The drug is currently not available through the NHS, and patients are forced to pay thousands of dollars each month out-of-pocket.

The UK experience provides a valuable lesson for the United States, one that Rep. Jayapal’s new bill has taken to heart: For a Medicare for All system to meaningfully lower prescription drug prices, it must give the government the power to put the patent at risk, not the patient. Otherwise, the government and patients will be forced to continue absorbing higher prescription drug costs or risk not having access to needed drugs.

In other countries, when competitive licenses are issued, they are deployed rarely and then usually rescinded once drug prices have been lowered. Furthermore, the amount drug companies spend on marketing exceeds the amount they spend on research and development. From 2006 to 2015, big pharmaceutical companies spent more on share buybacks and dividends than they did on research and development.

A recent study found that federally funded research contributed to the science that underlies every one of the 210 new drugs approved between 2010 and 2016. Given that the U.S. government, funded by taxpayers, already subsidizes so much research for pharmaceutical companies through the National Institutes of Health, it is a transparent lie for pharmaceutical companies to claim that they need to charge outrageous prices for the purposes of “innovation.”

Indeed, it is entirely possible to completely cut out the pharmaceutical companies by creating a new system where all research and development is publicly funded—and the prescription drugs developed are available at a fair price with no patents or exclusivity. Economist Dean Baker has estimated that the United States is likely to spend more than “$450 billion (2.2 percent of GDP) on prescription drugs this year. We would likely be spending less than $80 billion, a savings of $370 billion annually, if all drugs were sold in a free market without patents or related protections.”

Big pharma is out of excuses. The solutions Rep. Jayapal’s bill lays out for lowering the costs of prescription drugs are thoroughly practical. They will do a much better job at ensuring patients can access their medicines than the current system, which is rigged to benefit pharma CEOs and shareholders.

Lowering the cost of prescription drugs is essential to creating a strong Medicare for All system. With the government taking aggressive action to slash the cost of prescription drugs while making sure no one is unable to get their needed medicines, it will be that much easier to provide improved health care to every American as a fundamental human right.

This article was produced by Economy for All, a project of the Independent Media Institute.


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Alex Lawson

Alex Lawson

Alex Lawson is the Executive Director of Social Security Works, the convening organization of the Strengthen Social Security Coalition — a coalition made up of over 340 national and state organizations representing over 50 million Americans.

Advocates Cheer DOJ Reversal of Trump Policy Denying Asylum to Victims of Violence

"Now it's time to build on this progress," said one migrant rights campaigner. "We're ready to work with the administration to create an asylum system that provides every person a fair opportunity to apply for protection."

Brett Wilkins, staff writer ·


Activists Frustrated That Biden, Putin Won't Reduce Nuclear Arsenals

"Concerned citizens around the globe expect more than a general commitment to lay a foundation for status quo arms control," said the head of the International Campaign to Abolish Nuclear Weapons.

Jessica Corbett, staff writer ·


'Huge Day for Trans Youth' as Biden Administration Reverses Trump-Era Title IX GuidancebrettJun 16, 2021
LGBTQ
"All students—including LGBTQ+ students—deserve the opportunity to learn and thrive in schools that are free from discrimination," said Education Secretary Miguel Cardona.

Biden Urged to Embrace Top Democrat's Call to End Deadly US Sanctions Against Venezuela

"The terrible suffering and death that Venezuela has experienced in recent years is overwhelmingly a result of economic collapse and deprivation caused by U.S. sanctions."

Kenny Stancil, staff writer ·


Record Heat and Flimsy Power Grid Across US Illustrates Urgent Need for Green Infrastructure

"Texas' grid shutting down in both cold and heat," said one Democratic lawmaker, "underscores the facts we need to invest in clean and renewable energy infrastructure. Immediately."

Julia Conley, staff writer ·